A Phase II, Open-Label, Parallel Cohort Study Of Subcutaneous Amivantamab In Multiple Regimens In Patients With Advanced Or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer PALOMA-2

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05498428

Study #:
STUDY00150035

Start Date:
Mar 15, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05498428

View Complete Trial Details & Eligibility at ClinicalTrials.gov